PROTEASOME INHIBITORS AS REVERSERS OF RESISTANCE TO ARTEMISININ-BASED ANTIMALARIALS

Grant number: 1092808 | Funding period: 2015 - 2017

Completed

Abstract

Current antimalarial control is highly dependent on Artemisinin Combination Therapy (ACTs), which makes recent reports of decreased clinical efficacy of artemisinins extremely concerning. This project will develop proteasome inhibitors to synergise the activity of artemisinins - effectively reversing resistance. We will confirm that the selected compounds have good bioavailability, low cytotoxicity in human cell lines and efficacy in mouse models of malaria.

Related publications (4)

University of Melbourne Researchers